Durvalumab/tremelimumab
How it works
Durvalumab/tremelimumab is a combination of two immunotherapy drugs: durvalumab and tremelimumab. It works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells, and also by increasing the production of cytokines, which are signaling molecules that help to activate the immune system.
Cancer types
Efficacy
In clinical trials, durvalumab/tremelimumab improved overall survival in patients with pancreatic cancer, with approximately 26% of patients achieving a partial response.
Side effects
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.